Incretin levels in polycystic ovary syndrome
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Objective: Polycystic ovary syndrome (PCOS) has been linked to a high risk of type 2 diabetes mellitus. Disturbances in the secretion of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have been observed in states with impaired glucose regulation. This paper considers the secretion of GIP and GLP-1 after oral glucose load in a group of lean, glucose-tolerant PCOS women in comparison with age- and body mass index (BMI)-matched healthy women. Design: Case control. Methods: PCOS (n=21, 25.8±4.1 years, BMI 21.6±1.7 kg/m 2) and control healthy women (CT, n=13, 28.5±7.2 years, BMI 20.3±2.5 kg/m 2) underwent oral glucose tolerance test (OGTT) with blood sampling for glucose, insulin, C-peptide, total GIP, and active GLP-1. Insulin sensitivity was determined both at fasting and during the test. Statistics: Repeated measures ANOVA. Results: Glucose levels and insulin sensitivity did not differ between PCOS and CT. PCOS had significantly higher levels of C-peptide (P<0.05) and tended to have higher insulin levels. The levels of total GIP were significantly higher in PCOS than in CT (P<0.001). Active GLP-1 levels exhibited a significantly different time-dependent pattern in PCOS (P<0.002 for PCOS versus time interaction). GLP-1 concentrations were similar in PCOS and CT in the early phase of OGTT and then reached significantly lower levels in PCOS than in CT at 180 min (P<0.05). Conclusions: Increased total GIP and lower late phase active GLP-1 concentrations during OGTT characterize PCOS women with higher C-peptide secretion in comparison with healthy controls, and may be the early markers of a pre-diabetic state.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the first study, the Authors observed that GLP-1 levels were similar in PCOS and controls in the early phase of the 75-g oral glucose tolerance test (OGTT) until 60 min, but that GLP-1 levels were significantly lower after 180 min”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [45]
In the citing paper
“suggesting that women with PCOS might have reduced GLP-1 secretion in the late postprandial phase [45].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [45]
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931 · cited 1×
“Insulin sensitivity was assessed in fasting conditions with the quantitative insulin sensitivity index QUICKI ( 16 ), and in dynamic conditions with the oral glucose insulin sensitivity index (OGIS), which describes glucose clearance during the postprandial phase of the OGTT (17).”
MethodBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“Incretin hormones, GIP and GLP-1, are responsible for the augmentation of insulin secretion after oral glucose load ( 1 , 2). To the best of the authors’ knowledge, there is only one previous study of incretin hormones in a small group of lean PCOS, which found no difference in GIP or GLP-1 between PCOS and controls,…”
BackgroundInfluentialLegro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,516
Asunción, M., Calvo, R. M., San Millán, J. L., Sancho, J., Avila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,318
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062 · cited 2×
“Incretins are peptide hormones, secreted from the gut, responsible for the augmentation of insulin secretion after oral glucose intake (1, 2 ). Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), formerly known as gastric inhibitory polypeptide (GIP), are the most important of these.”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“Our results do on the other hand accord with other authors, describing increased GIP (20) and decreased active GLP-1 levels in patients with overt T2DM ( 21 ).”
ResultA Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test
Mari, A., Pacini, G., Murphy, E., Ludvik, B., & Nolan, J. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.539 · Cited by 806 · cited 1×
“Insulin sensitivity was assessed in fasting conditions with the quantitative insulin sensitivity index QUICKI (16), and in dynamic conditions with the oral glucose insulin sensitivity index (OGIS), which describes glucose clearance during the postprandial phase of the OGTT ( 17 ).”
MethodSelf-citation
Cited by
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
The crucial role and mechanism of insulin resistance in metabolic disease
Zhao, X., An, X., Yang, C., Sun, W., Ji, H., & Lian, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149239 · Cited by 557
“Moreover, insulin, as a reproductive as well as metabolic hormone, has direct effect of stimulating ovarian androgen production by stimulating 17a-hydroxylase activity in the ovarian theca cells and enhance the activity of insulin-like growth factor-1 (IGF-1) receptor in the ovary, thus increasing its free IGF level a…”
BackgroundObesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Cena, H., Chiovato, L., & Nappi, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa285 · Cited by 356
“Secretion of GLP-1 after oral glucose tolerance test (OGTT) was evaluated in a group of lean, glucosetolerant PCOS women in comparison with age- and BMI-matched healthy women (66).”
ResultHe, F.-F., & Li, Y.-M. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00670-3 · Cited by 289
“Also, insulin can enhance activity of insulin-like growth factor-1 (IGF-1) receptor in the ovary, which increase its levels of free IGF, promoting e production of androgen [34].”
BackgroundFernandez, R., Moore, V., Van Ryswyk, E., Varcoe, T., Rodgers, R., March, W., Moran, L., Avery, J., McEvoy, D., & Davies, M. (2018) · Nature and Science of Sleep · doi:10.2147/nss.s127475 · Cited by 137
Metadata
- Authors
- Vrbikova, J., Hill, M., Bendlova, B., Grimmichova, T., Dvorakova, K., Vondra, K., & Pacini, G.
- Affiliations
- Institute of Endocrinology (CZ)
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08
- Volume
- 159
- Issue
- 2
- Pages
- 121-127
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2132221299
- Cited by
- 81
- References
- 37
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 4 · 2023: 9 · 2022: 6 · 2021: 5 · 2020: 10 · 2019: 8 · 2018: 4 · 2017: 5 · 2016: 1 · 2015: 6 · 2014: 4 · 2013: 1 · 2012: 2
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- polycystic ovary syndrome, incretins, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, C-peptide, insulin sensitivity, oral glucose tolerance test, type 2 diabetes risk, prediabetes, lean women
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Female, Gastric Inhibitory Polypeptide, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Time Factors, Case-Control Studies, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incretin levels in polycystic ovary syndrome. https://app.cochat.ai/papers/10.1530/eje-08-0097
- The paper
- Vrbikova, J., Hill, M., Bendlova, B., Grimmichova, T., Dvorakova, K., Vondra, K., & Pacini, G. (2008). Incretin levels in polycystic ovary syndrome. European Journal of Endocrinology. https://doi.org/10.1530/eje-08-0097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.